🇺🇸 FDA

Intelligence · Clinical Pipeline

Autoimmune & immunology · Phase II

Autoimmune & immunology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
327

Quick answer

Autoimmune & immunology Phase II programs: NovaPharmaNews indexes 327 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 1 of 7

  1. -, MERCAPTOPURINE , -, Film-Coated Tablet without JNJ-77242113, JNJ-77242113, AZATHIOPRINE , METHOTREXATE , JNJ-77242113

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  2. -aminosalicylic acid

    Ultragenyx UK Limited

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  3. 608

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Axial Spondyloarthritis

    phase 2 small molecule active

    1 trial

  4. 626

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Systemic Lupus Erythematosus (SLE)

    phase 2 small molecule active

    1 trial

  5. 627

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Ulcerative Colitis (UC)

    phase 2 small molecule active

    1 trial

  6. 68Ga-FAPI-46, Sonelokimab

    MoonLake Immunotherapeutics

    psoriatic arthritis, axial spondyloarthritis

    phase 2 small molecule active

    1 trial

  7. 75mg SHP647 (PF-00547659)

    Takeda

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  8. 80 mg DR-6MP

    Teva Pharma GmbH

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  9. A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)

    Kyverna Therapeutics

    Lupus Nephritis

    phase 2 other active

    1 trial

  10. A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

    Amgen

    Ulcerative Colitis (UC)

    phase 2 other active

    1 trial

  11. A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

    Amgen

    Ulcerative Colitis (UC)

    phase 2 other active

    1 trial

  12. A-623

    Santhera Pharmaceuticals (Deutschland) GmbH

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  13. ABBV-066, Lutikizumab

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 2 small molecule active

    1 trial

  14. ABBV-066, Lutikizumab, ABBV-382, ABBV-066 / Risankizumab, ABBV-8736

    AbbVie Deutschland GmbH & Co. KG

    Moderate to Severe Crohn’s Disease

    phase 2 small molecule active

    1 trial

  15. ABBV-154

    AbbVie

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  16. ACP-044 Dose A

    Acadia Pharmaceuticals B.V.

    Osteoarthritis Pain

    phase 2 small molecule terminated

    1 trial

  17. ADX-629

    Aldeyra Therapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  18. AGMB-129

    Agomab Therapeutics NV

    Fibrostenotic Crohn's Disease

    phase 2 small molecule active

    2 trials

  19. ALPN-101

    Vertex Pharmaceuticals (Australia) Pty.

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  20. ALX-0061

    Sanofi Pasteur

    Lupus Erythematosus, Systemic

    phase 2 mab completed

    1 trial

  21. ALX-0600

    Takeda

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  22. ALXN 2050, ALXN2050 Placebo Tablets

    Alexion Europe SAS

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  23. AP1189 Tablet, AP1189 Tablet, AP1189 Tablet, Matching Placebo (tablets), Methotrexat-Ebewe, 2,5 mg, tabletki

    Lacuna Pharma Pty Ltd

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  24. APL-2

    Apellis Europe B.V.

    Warm Autoimmune Hemolytic Anemia

    phase 2 small molecule completed

    1 trial

  25. ARGX-117, ARGX-113

    argenx

    AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

    phase 2 small molecule active

    1 trial

  26. ARQ-151 cream 0.3%

    Arcutis Biotherapeutics

    Psoriasis

    phase 2 small molecule completed

    2 trials

  27. ARQ-151 cream 0.5%

    Arcutis Biotherapeutics

    Psoriasis

    phase 2 small molecule completed

    1 trial

  28. ASP5094

    Astellas Pharma Inc

    Rheumatoid Arthritis (RA)

    phase 2 small molecule completed

    1 trial

  29. ATI-450

    Aclaris Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  30. ATI-450

    Aclaris Therapeutics

    Psoriatic Arthritis

    phase 2 small molecule terminated

    1 trial

  31. ATI-450 50 mg oral tablet BID

    Aclaris Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  32. AUR200, Isotone Natriumchloridlösung 0,9 % Braun Injektionslösung

    Aurinia Pharmaceuticals

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  33. AUTO1, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludara 50 mg powder for solution for injection or infusion

    Autolus GmbH

    Systemic Lupus Erythematosus with Active Lupus Nephritis

    phase 2 small molecule active

    1 trial

  34. AZD1163 Placebo, AZD1163

    AstraZeneca AB

    Rheumatoid arthritis

    phase 2 small molecule active

    1 trial

  35. AZD7798 Placebo, AZD7798

    AstraZeneca AB

    Crohn's Disease

    phase 2 small molecule active

    1 trial

  36. AZD7798 Placebo: 0.9% saline solution for injection, commercially available., AZD7798

    AstraZeneca AB

    Crohn’s Disease and an Ileostomy

    phase 2 small molecule active

    1 trial

  37. Alicaforsen

    IONIS PHARMACEUTICALS INC

    Ulcerative Colitis

    phase 2 small molecule completed

    2 trials

  38. Allogeneic MSC (AlloMSC)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory Systemic Lupus Erythematosus

    phase 2 mab active

    1 trial

  39. Allogeneic NK Cells

    Artiva Biotherapeutics

    Refractory Rheumatoid Arthritis (RA)

    phase 2 small molecule active

    1 trial

  40. Andecaliximab

    Gilead Sciences Ireland UC

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  41. Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet

    Lacuna Pharma Pty Ltd

    Polymyalgia rheumatica

    phase 2 small molecule active

    1 trial

  42. Aritinercept

    Aurinia Pharmaceuticals

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  43. Atacicept 75 mg

    Serono Europe Limited

    Lupus Erythematosus, Systemic

    phase 2 small molecule terminated

    1 trial

  44. Atacicept Autoinjector Combination, Atacicept

    Vera Therapeutics

    Multiple Autoimmune Glomerular Diseases

    phase 2 small molecule active

    1 trial

  45. Autologous mesenchymal stem cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Autoimmune Diseases

    phase 2 other completed

    1 trial

  46. BGB-45035

    BEONE MEDICINES AUS PTY LTD

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  47. BI 3000202, BI 3000202, Placebo matching BI 3000202

    Boehringer Ingelheim

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial

  48. BMS-945429 Placebo

    CSL Behring GmbH

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many autoimmune & immunology Phase II programs exist?

327 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.